← Back to Company DatabaseVisit Website
Veracyte
Genomic diagnostics to improve cancer diagnosis and reduce unnecessary procedures.
PublicSouth San Francisco, CAFounded 2008
About
Veracyte develops genomic diagnostic tests that help physicians make more informed cancer treatment decisions and reduce unnecessary invasive procedures. Its products include tests for thyroid, lung, and other cancers that use gene expression analysis to classify suspicious lesions. The company acquired Decipher Biosciences and its prostate cancer genomic classifier in 2021.
Total Funding
$300MKey Product
Afirma and Decipher genomic classifiersGeography
North AmericaKey Investors
Wasatch Global InvestorsOrbiMedDeerfield Management
Focus Areas
DiagnosticsEarly Detection / Screening
Technology
Genomics / SequencingAI / Machine Learning
Cancer Types
LungProstatePan-cancer
Last updated: Feb 4, 2026